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Abstract
The DNA-dependent protein kinase (DNA-PK) is a pivotal component of the DNA repair
machinery that governs the response to DNA damage, serving to maintain genome integrity.
However, the DNA-PK kinase component was initially isolated with transcriptional complexes,
and recent findings have illuminated the impact of DNA-PK-mediated transcriptional regulation
on tumor progression and therapeutic response. DNA-PK expression has also been correlated with
poor outcome in selected tumor types, further underscoring the importance of understanding its
role in disease. Herein, the molecular and cellular consequence of DNA-PK will be considered,
with an eye toward discerning the rationale for therapeutic targeting of DNA-PK.
Over two decades ago, the DNA-dependent protein kinase (DNA-PK) was discovered and
characterized as part of SP1 transcription complexes [1] and as a regulatory component of
transcriptionally poised RNA polymerase II [2], but has been extensively studied with
regard to function in DNA double strand break repair. Recently, a plethora of studies
unveiled critical functions of DNA-PK outside the DNA repair process, redefining the
paradigm of DNA-PK activation and signaling. While much remains to be understood about
the cellular consequence of DNA-PK, studies to date have dramatic implications for the role
of this kinase in tumor progression and therapeutic response.
One mainstay of cancer treatment is induction of irreparable DNA damage. DNA-PK, a
serine/threonine protein kinase complex composed of a heterodimer of Ku proteins (Ku70/
Ku80) and the catalytic subunit DNA-PKcs, is a critical component of the response to
damage; as such, it is not surprising that DNA-PK correlates with decreased response to
DNA damaging agents and therapeutic resistance in multiple cancers [3–6]. Further,
utilization of aptamer-shRNA chimeras identified DNA-PK as an ideal radiosensitization
target in prostate cancer [7]. Less expected, however, is that DNA-PK is correlated with
poor prognosis independent of damage induction in numerous tumor types. DNA-PK is
elevated in esophageal cancer tissues compared to adjacent normal mucosae [8], and high
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tumor/normal expression ratio of DNA-PKcs in non-small cell lung cancer is associated
with a 2.13-fold increased risk of death [9]. Additionally, DNA-PKcs expression and
activity is higher in B-cell chronic lymphocytic leukemias that are positive for mutations
known to predict for short survival and chemoresistance [10]. The overexpression of DNA-
PK in cancer relative to normal tissue associated with poor prognosis has been suggested to
result from deregulation of transcription factors controlling gene expression [11], though
other mechanisms including gene amplification may play a role. These findings, combined
with evidence that DNA-PKcs is a potentially actionable therapeutic target [12, 13], have
prompted development of DNA-PK targeting strategies. Given the multitude of pathways
that drive cancer cell survival and progression, understanding mechanisms of DNA-PK
regulation and associated cellular consequences are critical to designing effective
therapeutic regimens to suppress DNA-PK. Herein, the pleiotropic roles of DNA-PK in
human tumorigenesis and progression will be discussed.
DNA-PK IN DNA REPAIR
DNA-PKcs is a member of the phosphatidylinositol 3-kinase-related (PIKK) family of
protein kinases and is abundantly expressed in almost all mammalian cells [14]. Of the six
members of the PIKK family of kinases, three play prominent roles in the response to
damage: DNA-PKcs and ataxia telangiectasia mutated (ATM) function primarily in double
strand break repair; while ataxia telangiectasia and Rad3 related (ATR) is activated by single
strand breaks, all three kinases share substrate homology (phosphorylation of S/TQ motifs)
[15]. Not surprisingly, these important kinases have been implicated in human diseases, as
germline mutations in ATM and ATR result in ataxia-telangiectasia and Seckel syndrome,
respectively [16, 17], and somatic mutations in ATM are frequently found in several tumor
types [18]. It is now also appreciated that germline mutations targeting DNA-PKcs lead to
severe combined immunodeficiency (SCID) [19], and selected somatic mutations in DNA-
PKcs have been speculated to interfere with double strand break repair and promote
genomic instability [20]. Identification of mutated DNA-PKcs, combined with the inverse
correlations seen between DNA-PKcs levels and overall survival in human cancers,
necessitates precise understanding of how DNA-PKcs functions both within and outside of
the damage response to effectively design therapeutic strategies.
Ku70 and Ku80 (also called Ku86) are encoded by the XRCC6 and XRCC5 genes in
humans, respectively, and have a strong affinity for free ends of DNA [21]. DNA-PKcs, a
469 kDa protein encoded by the PRKDC gene in humans, is composed of several distinct
functional domains (Figure 1A); in addition to a highly conserved catalytic kinase domain,
DNA-PKcs contains a large N-terminal domain containing mostly helical elements and
HEAT (Huntingtin, Elongation Factor 3, PP2A, and TOR1) repeats along with the JK, PQR,
and ABCDE phosphorylation clusters (groups of phosphorylation sites with important
regulatory functions), and two additional regions conserved amongst PIKK family members:
the FAT (named due to homology in this region between FAT, ATM, and TRRAP) domain,
and a short C-terminal region termed the FATC (FAT at the extreme C terminus) domain
[22]. The FAT and FATC domains surround the catalytic domain and serve to stabilize
conformational changes to the catalytic core and regulate kinase activity [23]. As the kinase
activity is crucial for roles both within and beyond the damage response, determination of
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the structure of DNA-PKcs has been critical in understanding regulation and function of the
protein, most particularly as related to human malignancy.
Role in NHEJ
The most well characterized function of DNA-PK is to mediate direct ligation of the broken
ends of DNA double strand breaks generated both endogenously (e.g. via production of
reactive oxygen species (ROS) during metabolism or via developmental VDJ recombination
in the immune system) and exogenously (e.g. via radiomimetic drugs, ionizing radiation).
Primarily, DNA-PK regulates repair of double strand breaks through the non-homologous
end joining (NHEJ) DNA double strand break repair pathway (previously reviewed in depth
[24]), a concept supported by the SCID phenotype of DNA-PKcs knockout mice resulting
from lack of VDJ recombination during development [25]. Briefly, NHEJ is initiated
through the recognition and binding of broken DNA ends by the ring shaped Ku70/Ku80
heterodimer, followed by recruitment of DNA-PKcs through its interaction with Ku and
DNA (Figure 1B, left). Recruitment of DNA-PKcs facilitates movement of the Ku
heterodimer into the DNA duplex, allowing DNA-PKcs to serve as a tether for the broken
DNA ends and prevent exonucleolytic degradation [26]. Binding to DNA promotes
activation of DNA-PKcs kinase activity, though the exact mechanism underlying this event
remains poorly understood. Once activated, DNA-PKcs phosphorylates and alters the
activity of proteins that mediate NHEJ, including Ku70, Ku80, Artemis, the X-ray cross
complementing protein 4 (XRCC4), the XRCC4-like factor (XLF), and DNA ligase IV
(LigIV); however, none of these phosphorylation events are independently required for
efficient NHEJ repair [27]. Activated DNA-PKcs also phosphorylates Ser139 on histone
variant H2AX (γH2AX) either directly or indirectly through Akt/GSK3b signaling [28].
γH2AX, a well known marker of DNA double strand breaks [29], aids in recruitment of
repair factors to double strand breaks [30] and coordination of signaling cascades required
for efficient repair [31].
Perhaps the most important substrate of DNA-PK is the kinase subunit itself, as
autophosphorylation is critical for regulation of end processing, enzyme inactivation, and
complex dissociation [32, 33]. The most well characterized autophosphorylation sites occur
at Ser2056 (PQR cluster) and Thr2609 (ABCDE cluster) [27, 34]. Studies suggest that
phosphorylation of the ABCDE cluster promotes access to DNA ends, while
phosphorylation of the PQR cluster blocks end access [35]; additionally, phosphorylation of
both clusters impacts dissociation of DNA-PKcs from DNA and subsequent loss of kinase
activity, though additional yet to be determined phosphorylation sites are likely also
involved [36, 37]. While these post-translational modifications are well understood, more
than 40 phosphorylation sites have been identified in vitro [38], and the impact of each on
DNA-PKcs function appears to be complex, leaving open the question as to which are
critical for tumor-associated activities. Similarly, the order of recruitment and function of
both processing and ligation factors involved in NHEJ after binding of Ku remain poorly
defined, and the process is likely more fluid and dynamic than strictly regimented. Still, it is
apparent that DNA-PKcs activation is required for repair, as pharmacologic inhibition of
DNA-PK kinase activity results in inefficient repair and hypersensitivity to double strand
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break-inducing agents [12, 13]. Thus, DNA-PKcs is required for direct ligation of broken
DNA ends, rendering it a critical factor in NHEJ.
Role in HR
In addition to its role in NHEJ, DNA-PK has also been implicated in the second major DNA
double strand break repair pathway, homologous recombination (HR) (Figure 1B, right).
Evidence for a definitive role for DNA-PK in alternative end-joining, a double strand break
repair pathway thought to function when NHEJ and HR fail, remains inconclusive. While
NHEJ is error-prone (since this class of repair does not utilize sequence homology and
brings together broken ends of DNA, regardless of position or sequence) and occurs during
all phases of cell cycle, HR involves Rad51-mediated strand invasion into a homologous
strand of DNA that is employed as a template, resulting in accurate repair that occurs
primarily during the G2/M phases of cell cycle when undamaged sister chromatids are
available [39]. Outside of the obvious cell cycle constraints, the mechanisms underlying
selection of HR or NHEJ for double strand break repair remain incompletely defined. One
factor identified to influence this choice is DNA end resection, as blunt, minimally
processed DNA ends are repaired by NHEJ, while 3′ end resection is required for loading of
Rad51 in order for HR to occur [40]. End resection is controlled by interplay between
53BP1 and BRCA1, with 53BP1 supporting NHEJ by suppressing end resection while
BRCA1 promotes CtBP-interacting protein (CtIP) and EXO1-mediated end resection
through recruitment of the MRE11-RAD50-NBS1 (MRN) complex [41]. MRE11 is
particularly important in the initial response to damage, as the endonuclease and
exonuclease activities of MRE11 sequentially mediate resection of the DNA end [42] and
MRE11 promotes pro-survival Akt-S473 phosphorylation in response to double strand
breaks [43]. Factors influencing competition between 53BP1 and BRCA1 at double strand
breaks include spatial dynamics and regulation by cell cycle specific factors, though other
mechanisms yet to be determined likely are also involved [44]. Chromatin complexity likely
also plays a role in selection of repair pathway, as HR repairs heterochromatin-associated
double strand breaks during the G2 phase of cell cycle [45].
It has been postulated that NHEJ serves as the default pathway of double strand break repair,
with HR occurring only when NHEJ fails [46]. This supposition is supported in part by the
observation that Ku70, Ku80, and DNA-PKcs are abundant in mammalian cells [27] while
HR factors are expressed to a lesser degree and in a cell cycle specific manner [47].
Moreover, Ku is recruited within minutes to sites of damage and NHEJ can be completed in
approximately 30 minutes, while Rad51 foci form approximately 2 hours post damage
induction and HR takes at least 7 hours to complete [48]. While NHEJ has been
demonstrated to be the dominant mechanism of double strand break repair, a functional HR
pathway is critical for viability [48], suggesting a mechanism by which HR can be activated
even if NHEJ machinery is targeted to damage first. Initial attempts to address the question
as to whether there is a direct role for DNA-PKcs in promoting HR failed to definitively
determine whether it is the kinase activity of DNA-PKcs or simply the failure of NHEJ that
promotes HR [27, 49]. Additional studies identified the JK cluster (Thr946 and Ser1004)
and Thr3950 as DNA-PKcs phosphorylation sites that specifically promote HR while
inhibiting NHEJ, thus providing a mechanism to protect certain DNA ends from repair by
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NHEJ [50]. While evidence suggests that phosphorylation of Thr3950 is an
autophosphorylation event [35], the impact of different protein kinases on these regulatory
sites remains under investigation [27]. In sum, these findings clearly define a function for
DNA-PKcs outside of its classically defined role in NHEJ. Consonantly, it is increasingly
appreciated that DNA-PKcs functions in a variety of capacities outside of NHEJ [51]. These
novel functions of DNA-PKcs and mechanisms of regulation illustrate the versatility of the
kinase and identify DNA-PK as a potential therapeutic target for a variety of human
malignancies.
REGULATION OF DNA-PK ACTIVITY
Given the critical role of DNA-PK in both NHEJ and HR, recent emphasis has been placed
on identifying the mechanisms that control DNA-PKcs kinase activity. In addition to
autoregulation, both kinase and non-kinase factors have been implicated as key modulators
of DNA-PKcs activity in human cells.
Autoregulation
While it is well accepted that Ku-mediated binding of DNA-PKcs to broken DNA ends
results in DNA-PKcs activation, the precise mechanism underlying the activation event
remains unknown. Several recent reports provide insight into the mechanism and identify
Ku-independent factors that modulate DNA-PKcs activity (Figure 2). Contrary to the
paradigm that binding to DNA is a requirement for DNA-PKcs activation, it was
demonstrated that DNA-PKcs autophosphorylation can be modulated by N-terminal
conformational changes in the protein (such as that likely caused by DNA binding) [52].
This supposition was further supported by findings which revealed that the N-terminus (but
not the C-terminus) is required for binding to the Ku-DNA complex and robust DNA-PKcs
activity [53]. These collective studies support the concept that the N-terminus of DNA-PKcs
is crucial for both targeting to Ku-bound DNA, and for conformational change-induced
enzymatic activity.
Cancer-associated survival factors
Consistent with a pro-tumorigenic role for DNA-PK, a number of canonical pro-survival
signaling pathways have been shown to regulate DNA-PKcs kinase activity. The serine/
threonine kinase Akt has been linked to NHEJ [54], and a recent report revealed that Akt1
forms a complex with DNA-PKcs as an initiating step in repair after IR. Akt1 promotes
DNA-PKcs autophosphorylation and was critical for recruitment of the Akt1/DNA-PKcs
complex to broken DNA ends [55]. Additionally, epidermal growth factor receptor (EGFR)
can bind DNA-PKcs and enhance DNA-PKcs activity in response to damage [56]. As Akt
can be activated by EGFR ligands [57], coordinated regulation between EGFR and Akt may
be important for full DNA-PKcs activation in response to damage, though this putative
pathway requires more rigorous depth of investigation. Further, as DNA-PKcs activity
results in Akt-S473 phosphorylation in response to damage in a cell line specific context
[58], there appears to be a positive feedback loop involving DNA-PKcs and Akt that may
play a role in the response to DNA damage. Despite these intriguing findings, DNA-PKcs
activation does not appear to be a general response to pro-survival signaling, as inhibition of
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MEK or knockdown of ERK1 or ERK2 results in enhanced etoposide induced activation of
DNA-PKcs and increased double strand break repair, while constitutively active ERK
reduced DNA-PKcs activation and subsequent double strand break repair [59]. Thus, DNA-
PKcs activation is selectively regulated by factors involved in multiple pro-survival
signaling pathways, which may serve as proximal effectors of the damage response and alter
tumor cell behavior.
Casein kinase II
Kinases linked to enhanced cell cycle progression may also alter DNA-PKcs activation,
including casein kinase II (CK2), a constitutively active serine/threonine kinase known to
play a role in cancer-associated processes. CK2 was shown to interact with DNA-PKcs, and
this interaction increases after DNA damage. Conversely, depletion of CK2 inhibits both
DNA damage-induced DNA-PKcs S2056 autophosphorylation and double strand break
repair in DNA-PKcs proficient cells [60], suggesting that CK2 plays a pivotal role in DNA-
PKcs activation. The mechanism was recently identified, wherein CK2 was shown to co-
localize with γH2AX at sites of DNA damage and likely stabilize the interaction between
DNA-PKcs and Ku80 at broken DNA ends, resulting in enhanced DNA-PKcs activation in
response to double strand breaks [61]. Notably, CK2 depletion results in induction of
autophagy, decreased phosphorylation of S6 and Akt kinases, and increased phosphorylation
and activity of ERK1/2 [62]; since Akt positively contributes to DNA-PKcs activation while
MEK-ERK has the opposite effect, the data suggest that a coordinated mechanism of
regulation between CK2 and the Akt and MEK-ERK signaling pathways may influence
DNA-PKcs activation.
Non-kinase modulators
Non-kinase factors with roles in malignancy have also been identified as modulators of
DNA-PKcs. Protein phosphatase 6 (PP6) is recruited to sites of damage and contributes to
DNA-PKcs activation through direct interaction [63]. PP6 also influences the response to
damage by dephosphorylating Ser139 of γH2AX, resulting in dissolution of IR induced
γH2AX foci and release of cells from damage response associated checkpoints [64].
However, it was only recently determined that the regulatory subunit SAPSR1 (R1) of PP6
facilitates a bidentate mechanism of binding to DNA-PK that is necessary for the interaction
with PP6 [65]. Thus, R1 influences DNA-PKcs activation by bridging PP6 and DNA-PK in
response to damage.
Finally, the RNA-binding protein nuclear factor 90 (NF90) was recently shown to modulate
DNA-PKcs activity. NF90 exists in a heterodimeric complex with NF45 and has been
implicated in regulation of gene expression [66]. Surprisingly, immunodepletion or RNA
digestion of NF90/NF45 reduced DNA end joining to a similar extent as DNA-PKcs
immunodepletion, and NF90/NF45 depletion caused increased sensitivity to IR and elevated
levels of γH2AX foci [67]. Though this does not directly implicate NF90/NF45 in DNA-
PKcs activation, these findings do suggest that the NF90/NF45 complex may regulate DNA-
PKcs mediated DNA damage repair. Combined, all of these observations indicate that DNA-
PKcs activation is not merely the result of binding to broken DNA ends; rather, DNA-PKcs
activation appears to be a complex process influenced by a variety of pro-tumorigenic
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factors, suggesting that cancer cells may select for enhanced DNA-PKcs activity. Clearly,
additional studies are required for a complete understanding of the mechanisms governing
DNA-PKcs activation and consequent downstream cellular effects of DNA-PKcs.
DNA-PK: CELLULAR CONSEQUENCES
As the mechanisms regulating DNA-PKcs activation continue to be characterized, it is
apparent that in addition to DNA double strand break repair, DNA-PKcs influences a variety
of critical cellular processes associated with malignancy (Figure 3). Specifically, genomic
instability, hypoxia, metabolism, and inflammatory response are all impacted by DNA-PKcs
activity, and likely promote DNA-PKcs-associated tumor phenotypes.
Genomic stability
A process tightly associated with the response to DNA damage is maintenance of genomic
stability. Primarily, the cellular response to damage is checkpoint activation, which serves to
maintain genomic stability and protect against gross genomic rearrangements [68].
However, deregulation of cell cycle checkpoints in the presence of incomplete or inaccurate
repair results in inappropriate cell proliferation and survival, and failure to efficiently repair
damage promotes errors in DNA replication and chromosome segregation [69]. As NHEJ
consists of indiscriminately ligating together broken DNA ends, this repair process can
result in loss of nucleotides from the DNA strand. Further, as sequence homology is not
required, direct ligation of double strand DNA breaks can promote deleterious
rearrangements and chromosomal translocations at sites where multiple double strand breaks
exist in close proximity, resulting in genomic instability. At a basic level, DNA-PKcs
influences maintenance of genomic stability through its indispensible role in the error prone
NHEJ pathway. However, recent reports indicate that DNA-PKcs may directly impact
genomic stability through additional means.
One mechanism by which DNA-PK impacts genomic stability is through interaction with
factors known to promote cancer progression. Snail1 is an E-box binding transcription factor
known to promote epithelial-mesenchymal transition (EMT) during development and
progression of cancer [70]. A recent report implicated interaction between Snail1 and DNA-
PKcs as a driver of genomic instability and aggressive tumor characteristics [71]. DNA-
PKcs was shown to interact with and phosphorylate Snail1 in response to damage, an event
that stabilized Snail1 and reciprocally inhibited DNA-PKcs activity. Further, Snail1
overexpression increased chromosomal aberrations in both the absence and presence of
damage and increased survival after damage, effects that were not observed in cell lines
lacking DNA-PKcs. Combined, these findings suggest that DNA-PKcs plays a crucial role
in Snail1-mediated genomic instability and resistance to genotoxic agents, possibly through
direct interaction and reciprocal regulation between the two proteins.
DNA-PKcs also functions in chromosomal integrity during transition through mitosis.
Exemplifying this, DNA-PKcs was found to be activated and closely associated with the
spindle apparatus at centrosomes and kinetochores during progression through mitosis [72].
DNA-PKcs inhibition resulted in dysfunctional chromosome alignment, suggesting that
DNA-PKcs activation is a critical regulator of microtubule dynamics during normal cell
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cycle progression through mitosis. Interestingly, a contrasting role for DNA-PKcs in
regulation of mitotic entry during replication stress was identified. Interruption of replication
machinery through a variety of mechanisms results in accumulation of single strand DNA
bound by replication protein A (RPA), which triggers ATR activation and phosphorylation
of the RPA32 subunit of RPA, resulting in checkpoint activation and cell cycle arrest [73].
Mutation in RPA32 phosphorylation sites targeted by DNA-PKcs resulted in decreased ATR
signaling and increased proportion of cells in mitosis due to a G2/M arrest defect. Further,
cells with mutant RPA32 or DNA-PKcs demonstrated inability to repair damage and
inappropriate entry into mitosis in response to stress, revealing a critical role for DNA-PKcs
in regulating mitotic entry in the presence of damage [74]. Thus, DNA-PKcs differentially
regulates entry into and progression through mitosis dependent on the presence or absence
of damage, defining a role for DNA-PKcs in maintaining chromosomal integrity and
preventing genomic instability. In sum, while DNA-PKcs guards against chromosomal
aberrations both in the presence and absence of damage, this complex may contribute to
genomic instability through interaction with Snail1, underscoring the multi-faceted nature of
DNA-PKcs activity. Perhaps these contrasting roles also reflect alterations in DNA-PKcs
function in diseases including cancer, as the protective role may be lost and damaging role
gained as a function of tumor progression.
Hypoxia
While mechanisms of activation in response to damage and maintenance of genomic
stability are often considered parallel pathways, it has become evident that DNA-PK
functions outside of the classical DNA damage response mechanisms. Hypoxia is a frequent
physiological occurrence and hypoxic response plays a critical role in human cell biology
and disease, particularly in cancer where solid tumors consume high amounts of oxygen
despite inadequate vascularization. One critical regulator of the cellular response to hypoxia
is hypoxia-inducible factor-1 alpha (HIF-1α), a transcription factor linked to numerous
cancers that activates a number of oxygen-related genes required for adaptation to hypoxic
conditions after induction by low oxygenation [75]. DNA-PKcs was found to be activated
by hypoxia, independent of DNA double strand breaks, but dependent on histone
acetylation, which is increased in hypoxic cells. DNA-PKcs positively regulated HIF-1α,
resulting in modulation of oxygen-sensing and response pathways [76]. Moreover, hypoxia-
induced γH2AX foci formation was delayed by depletion of HIF-1α or HIF-2α, though the
factor directly responsible for phosphorylating H2AX was not investigated [77]. Combined,
these studies present the novel concept that coordinated regulation between DNA-PKcs and
the HIF family of transcription factors may influence cellular response to oxygen depletion.
DNA-PK activation by hypoxia also impacts cellular responses independently of HIF.
Another factor recently implicated in hypoxic response is RPA70, a subunit of RPA
(discussed above), which has been shown to increase DNA repair in cancer cells [78].
RPA70 is normally bound to the tumor suppressor p53, but this interaction is disrupted by
hypoxia. A recent report demonstrated that DNA-PK phosphorylates p53 on Ser15, a crucial
event in dissociating RPA70 from p53 [79]. RPA70 gene silencing resulted in increased
apoptosis in resistant hypoxic cancer cells, revealing that DNA-PK phosphorylation of p53
results in p53-RPA70 dissociation and RPA70 mediated resistance to apoptosis under
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hypoxic conditions. In sum, these studies demonstrate that DNA-PK activation by histone
acetylation during hypoxia influences cellular survival through both HIF-dependent and
HIF-independent mechanisms.
Metabolism
A highly regulated and coordinated metabolic network of enzyme-catalyzed reactions exists
in all living organisms to efficiently manage constant energy needs. Given the increasingly
appreciated dynamic role of DNA-PK in cellular processes, it is not surprising that DNA-PK
influences such a critical pathway. While DNA-PK has been implicated in transcriptional
regulation of genes involved in lipogenesis [80], a recent report defines a general role for
DNA-PK in metabolic regulation. AMP-activated protein kinase (AMPK) is an energy
sensor that acts as a metabolic master switch influencing numerous processes [81]. DNA-
PKcs interacts with the regulatory λ1 subunit of AMPK, and glucose-deprivation stimulated
phosphorylation of AMPK is decreased in DNA-PKcs deficient cells [82]. Further, DNA-
PKcs inhibition or depletion resulted in reduced AMPK phosphorylation and activation in
response to glucose deprivation, suggesting that DNA-PKcs positively regulates AMPK
phosphorylation and activation in glucose-deprived conditions. As AMPK is a major factor
in cellular response to fluctuating energy levels, this finding reveals a significant role for
DNA-PKcs in metabolic regulation, particularly in the high-energy need tumor environment.
Innate Immunity/Inflammatory Response
The innate immune system is a first line of defense against pathogens, protecting a host from
infection in a non-specific way. The initial step in the innate immune response is detection
of pathogen specific antigens (particularly viral nucleic acids), and recognition of single and
double-stranded RNA substrates leads to transcriptional activation of anti-viral genes
mediated by nuclear factor-kappa B (NF-κB) and interferon regulatory factor (IRF) families
of transcription factors [83]. While DNA-PK has previously been demonstrated to be critical
for NF-κB mediated expression of VCAM-1 in response to treatment with the cytokine
tumor necrosis factor (TNF) [84], a novel role for DNA-PK in activation of innate immunity
and inflammation response independent of NF-κB was revealed in studies wherein DNA
from various pathogens was found to be bound by DNA-PK, resulting in IRF-3 mediated
transcription of multiple cytokine and chemokine genes independent of DNA-PKcs kinase
activity [85]. DNA-PKcs depletion produced diminished cytokine responses to DNA and
DNA viruses but not to RNA or RNA virus infection, supporting the concept that DNA-
PKcs recognition of foreign DNA is crucial. Further investigation revealed that stimulator of
interferon genes (STING) interacts with the DNA-PK complex but is dissociated after
introduction of DNA, suggesting that STING is released and able to activate IRF-3 mediated
transcription after binding of DNA-PKcs to DNA. These unexpected findings reveal a
critical role for DNA-PK in binding foreign DNA and activating the innate immune system
and subsequent inflammatory response, and point to a role in DNA-PK potentially impacting
tumor-associated inflammation.
Thus, DNA-PK modulates numerous important cellular processes, as the protein both guards
against and promotes genomic stability in a context dependent fashion, regulates hypoxic
response through HIF-dependent and independent mechanisms, impacts metabolism through
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interaction with AMPK, and activates the innate immune system in response to foreign
DNA. Strikingly, however, a major function of DNA-PK in human disease is the ability to
regulate gene expression.
DNA-PK AS A TRANSCRIPTIONAL MODULATOR
Prior to characterization of the damage response role, DNA-PK was originally identified in
complex with and shown to phosphorylate the transcription factor SP1 [1], along with being
identified as a regulatory component of transcriptionally poised RNA polymerase II [2].
Further, it has been reported that activation of transcription results in induction of double
strand breaks and recruitment of damage response machinery (including DNA-PK) [86],
suggesting interaction between transcriptional networks and DNA-PK. Given the ability of
Ku and DNA-PKcs to bind DNA double strand ends with high affinity, the context of
binding (i.e. end binding versus transcription specific binding) should be considered and
studies based on binding to double strand DNA interpreted with some degree of caution.
Still, it is now clear that DNA-PK directly impacts transcriptional regulation, interacting
with both the transcriptional machinery and transcription factors that alter cellular outcomes
(Figure 4). Given that transcription is perhaps the most fundamental mechanism underlying
cellular behavior and fate, the role of DNA-PK in regulating this process appears to have
critical implications for cancer cell behavior and disease progression.
Basal transcriptional machinery
RNA polymerase II (RNAPII), in complex with a set of general transcription factors and
regulatory proteins, is recruited to promoter regions of DNA where it catalyzes transcription
of RNA. It is generally appreciated that processively elongating RNAPII contains a
hyperphosphorylated carboxy-terminal domain (CTD) while paused RNAPII possesses a
hypophosphorylated CTD [87]. Previous observations have reported that DNA-PKcs
phosphorylates the RNAPII CTD and that DNA-PKcs and Ku are components of the
RNAPII holoenzyme [2, 88]. While the mechanism and functional consequence of DNA-PK
communication with RNAPII has yet to be fully elucidated, two major lines of investigation
found an interaction between DNA-PK and RNAPII that implicates DNA-PK as a
transcriptional regulator. First, DNA-PK functionally interacts with RNAPII during human
immunodeficiency virus (HIV) transcription. A recent study demonstrated that DNA-PK
modulates HIV gene expression and interacts with the RNAPII complex at the HIV long
terminal repeat (LTR), identical sequences used by viruses to insert genetic material into
host genomes [89]. DNA-PK is recruited to and forms a complex with RNAPII both at the
promoter and downstream regions of the HIV LTR, resulting in phosphorylation of specific
residues on the RNAPII CTD. Knockdown of DNA-PKcs resulted in decreased HIV gene
expression and replication, suggesting that DNA-PKcs plays an important role in both
processes. Further, analysis of interplay between DNA-PK and Tat, a protein crucial for
efficient HIV transcriptional elongation previously reported to interact with DNA-PK,
revealed that DNA-PKcs mediated phosphorylation of Tat is required for full HIV LTR
promoter transactivation. Thus, DNA-PKcs regulates transcription and replication of HIV
directly through phosphorylation of the CTD of RNAPII and indirectly through
phosphorylation of Tat, a factor critical for efficient transcriptional elongation. These
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findings provide rationale for treatment of HIV through DNA-PK inhibition, a concept that
should be more thoroughly explored in future studies.
A more recent study revealed a role for DNA-PK in modulating RNAPII transcriptional
activity at sites of broken DNA within coding regions of genes. Previous reports
demonstrated that double strand breaks transiently repress RNAPI and RNAPII
transcriptional machinery, and that breaks upstream of the promoter of an RNAPII reporter
gene inhibited transcription elongation dependent on ATM signaling [90]. However, the
impact of a single double strand break encountered during transcriptional elongation on
RNAPII was not addressed. Introduction of a single double strand break by a site-specific
meganuclease resulted in inhibition of transcription elongation followed by reinitiation [91].
Surprisingly, transcription inhibition was dependent on DNA-PKcs and not ATM, as
RNAPII remained associated with the promoter and body of the genes being transcribed
after inhibition of DNA-PKcs (but not ATM) activity. DNA-PKcs-dependent RNAPII
removal was shown to require the proteasome, as treatment with the proteasome inhibitor
MG132 or knockdown of a core subunit of the 19S proteasome complex (PSMD4) rescued
transcriptional arrest. Combined, these results suggest that DNA-PKcs is required for
eviction of RNAPII from DNA during elongation upon encountering a DNA lesion through
a process that likely involves proteasome-mediated destabilization of the RNAPII complex.
This defines an interaction between DNA-PKcs and RNAPII in a more general context, and
demonstrates that DNA-PKcs may directly modulate RNAPII-mediated transcription in a
variety of environments, including tumor-driven transcriptional networks.
Immune-related transcriptional networks
One important transcription factor regulated by DNA-PK is autoimmune regulator (AIRE), a
transcriptional activator that mediates central tolerance in the thymus by activating
expression of tissue-restricted antigen (TRA) genes [92]. Recruitment of AIRE to its
transcriptional targets is dependent on DNA-PKcs, as assembly and activity of AIRE on
DNA was abrogated in cells lacking DNA-PKcs [93]. Tethering of AIRE to DNA restored
transcriptional activity in the absence of DNA-PKcs, suggesting that DNA-PKcs functions
largely to direct AIRE to sites of transcriptional activation. An additional study utilizing
AIRE-deficient cells stably transfected with AIRE demonstrated that DNA-PKcs depletion
resulted in diminished transcriptional activity at promoters and decreased expression of Toll-
like receptor (TLR) 1, TLR3, and TLR8, receptors known to play roles in the innate immune
system [94]. As DNA-PKcs and AIRE were also demonstrated to directly interact, these
findings suggest that DNA-PKcs regulates AIRE-mediated expression of TLRs. Combined,
these studies reveal that DNA-PKcs is a critical modulator of the innate immune system
through regulation of AIRE-mediated transcriptional networks.
Tumor suppressors
DNA-PK has also been implicated directly in cancer-associated transcriptional regulation,
exemplified by influence on the p53 tumor suppressor. In general, p53-mediated activation
of cell cycle arrest is dependent on expression and activation of the cyclin-dependent kinase
inhibitor CDKN1A (p21Cip1) while apoptosis is mediated by expression and activation of
pro-apoptotic genes including Bax and p53 upregulated modulator of apoptosis (PUMA).
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Analysis of the mechanism underlying p53-mediated expression of p21Cip1 revealed
recruitment of DNA-PKcs and interaction with p53 at the p21Cip1 promoter after treatments
that promoted apoptosis but not after treatments that promoted cell cycle arrest [95].
Inhibition of DNA-PKcs kinase activity blocked DNA-PKcs binding to p53 on the p21Cip1
promoter, resulting in increased p21Cip1 transcription and reduction in cell death after pro-
death treatments. In sum, these findings demonstrated that DNA-PKcs negatively regulates
p21Cip1 expression through modulation of p53 at the p21Cip1 promoter, resulting in
induction of apoptosis after pro-death treatments. Interestingly, DNA-PKcs recruitment to
the Bax or PUMA promoters after pro-death treatments were negligible relative to
recruitment to the p21Cip1 promoter, revealing that DNA-PKcs regulation of p53 mediated
induction of apoptosis is specific to certain genes. This specific recruitment of DNA-PKcs to
negatively regulated p53 target gene promoters suggests that DNA-PKcs regulation of p53
targets occurs only when transcription is repressed, though the co-regulation between DNA-
PKcs and p53 is likely complex and warrants further investigation. Further, negative
regulation of p21Cip1 suggests that DNA-PKcs may coordinate expression of cell cycle
machinery to damage response in conditions that promote cell cycle arrest and repair,
though the DNA-PKcs-p53 connection is likely not a factor in G1 cell cycle arrest as DNA-
PKcs deficient cells do not exhibit a defective G1 arrest [96].
Complementing these findings, it has been suggested that DNA-PK regulation of p53
transcriptional activity may also be dependent on histone modifications at target genes.
Linker histone H1 regulates chromatin competency through binding to linker DNA [97].
One isoform, linker histone H1.2, inhibits p53-dependent transcription through alterations in
chromatin remodeling, and detailed investigation revealed that p300-mediated p53
acetylation in combination with DNA-PK phosphorylation of histone H1.2 at T146 relieved
H1.2 binding to p53, resulting in activation of p53 transcriptional activity [98]. Combined,
these studies demonstrate that DNA-PK modulates p53-mediated transcription through both
direct interaction with p53 at target genes and phosphorylation of histones that relieve
repressive interactions between p53 and chromatin. Thus, while the mechanisms are likely
complex and context dependent, DNA-PK plays a role in regulation of p53-mediated
transcription in response to damage.
Hormone receptors and hormone dependent cancers
The class I nuclear hormone receptor superfamily is a group of related transcription factors,
many of which are impacted by DNA-PK. Reports from over 15 years ago first
demonstrated interaction between DNA-PK and hormone receptors, as DNA-PK was shown
to phosphorylate both the rat glucocorticoid receptor and the chicken progesterone receptor,
the latter of which impacted transcriptional activation of the receptor [99, 100]. However,
only recently have new findings clearly defined a role for DNA-PK in transcriptional
regulation of hormone receptors in human cells and demonstrated consequence for human
malignancy.
The androgen receptor (AR) is a hormone receptor whose activity drives growth, survival,
and progression of prostatic adenocarcinoma (PCa) at all stages of disease. A recent study
demonstrated that AR is activated in response to genotoxic insult, driving expression of
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multiple genes critical for damage repair including DNA-PKcs [101]. AR activation was
also shown to positively regulate DNA-PKcs activity, possibly through modulation of Ku70
levels. DNA-PKcs depletion or inhibition resulted in inability to repair damage and
decreased overall survival in response to genotoxic insult, revealing that DNA-PKcs
expression and activity is critical for efficient AR-mediated repair after damage. Further,
DNA-PKcs was determined to be a coactivator of AR transcriptional activity, as DNA-PKcs
depletion resulted in a significant decrease in expression of multiple AR target genes.
Combined, these findings suggest that DNA-PKcs enhances AR transcriptional activation
and that AR driven DNA-PKcs expression and activity is required for AR-mediated DNA
repair, resulting in a positive feedback circuit that drives survival after damage.
The concept that DNA-PKcs modulates transcriptional activation in PCa is supported by
findings that identified a role for DNA-PKcs in regulation of the ETS family of transcription
factors, which are aberrantly expressed in a number of cancers. Notably, many prostate
cancers exhibit gene rearrangements fusing AR target genes to ETS transcription factors,
which result in elevated levels of ETS proteins driven by AR activity [102]. ETS factors
induce a transcriptional program enriched for invasion-associated genes, and overexpression
of ETS gene fusion proteins may contribute to cancer progression [103, 104]. ERG, the most
frequently overexpressed ETS protein, was shown to interact with DNA-PKcs, and ERG-
mediated transcription and consequential cell invasion, intravasation, and metastasis
required DNA-PKcs and poly(ADP-ribose) polymerase 1 (PARP1) [105]. Functional
association between DNA-PKcs and PARP1 is supported by studies reporting direct
interaction between DNA-PKcs and PARP1 [106] and cooperation between DNA-PKcs and
PARP1 to inhibit ribosomal RNA (rRNA) synthesis after DNA damage [107]. Thus, in
addition to modulating AR transcriptional activity, DNA-PKcs cooperates with PARP1 to
regulate ERG-mediated transcription, clearly defining DNA-PKcs as a regulator of
transcription in PCa. Further, PARP1 has also been shown to be critical for AR
transcriptional function and maintenance of AR-dependent cancer phenotypes, including
tumor progression [108]. Combined, these findings suggest a model of coordinated
regulation between AR, DNA-PKcs, and PARP1 that drives transcriptional networks in PCa.
Estrogen exerts its effects through estrogen receptor alpha and beta (ERα and ERβ), which
differentially impact proliferation. ERα controls transcriptional programs driving cell cycle
progression and proliferation and has been implicated in development and progression of
disorders including breast cancer (BCa) and cardiovascular disease. Within the last several
years, it was demonstrated that DNA-PK regulates ERα transcriptional activity. Initial
findings demonstrated that in response to estrogen stimulation, DNA-PK interacts with and
phosphorylates ERα at Ser118, resulting in stabilization of the ERα protein. Depletion of
DNA-PKcs resulted in decreased ERα transcriptional activation, suggesting that ERα-
mediated transcription is at least partially dependent on DNA-PKcs [109]. Additionally, a
second report discovered two ERα binding sites in a region upstream of the DNA-PKcs
transcriptional initiation site [110]. Estrogen-mediated ERα activation resulted in enhanced
DNA-PKcs promoter activity and increased levels of DNA-PKcs while ERα inhibition or
knockdown reduced DNA-PKcs expression, demonstrating that activated ERα
transcriptionally regulates DNA-PKcs levels. Combined, these studies reveal that DNA-
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PKcs modulates ERα transactivation and define a circuit of regulation between ERα and
DNA-PKcs, similar to that seen with AR and DNA-PKcs.
Most recently, cell-free biotin-estrogen response element (ERE) pulldown assays further
characterized the mechanism underlying DNA-PKcs influence on ERα transcriptional
activity, revealing that DNA-PKcs is responsible for recruitment of critical cofactors to
regulatory regions of ERα target genes [111]. Addition of ATP to initially stable ERα-
coregulator complexes resulted in immediate dismissal of five coregulators, including the
corepressors RIP40 and the CtBPs, and phosphorylation of multiple coregulators, including
transcriptionally activating sites on SRC-3, ERα, and MED1. DNA-PKcs depletion or
inhibition prevented both dismissal of RIP140 and phosphorylation of the transcriptionally
activating sites on SRC-3, MED1, and ERα, and similar complex formation was seen at a
naturally occurring ERE containing enhancer. Thus, these findings build on previous studies
reporting interaction between DNA-PKcs and ERα and provide mechanistic insight into
how DNA-PKcs regulates ERα-mediated transcription, suggesting that DNA-PKcs
phosphorylates SRC-3 and MED-1 for activation and RIP140 for dismissal from coregulator
complexes.
TARGETING DNA-PK IN CANCER
Identification of defined roles for DNA-PK in tumor associated processes including genomic
stability, hypoxia, metabolism, inflammatory response, and transcription supports targeting
DNA-PK as a therapeutic intervention in human malignancy. The therapeutic efficacy of
targeting DNA-PK has classically been gauged through potential to prevent repair of
damage, given the importance of DNA-PK activity in NHEJ. Consistent with this concept,
synthetic lethal interactions have been identified between DNA-PKcs and multiple damage
response factors including ATM, MSH3, and numerous components of HR-mediated repair
[112–114], suggesting that DNA-PK inhibitors may show efficacy as targeted agents for
treatment of damage repair-defective human cancers. While many of the original DNA-PK
inhibitors suffered from lack of specificity and poor pharmacokinetics, more recently
developed inhibitors, including NU7026 and NU7441, demonstrate improved specificity and
pharmaceutical properties and have been used preclinically to explore the impact of DNA-
PK inhibition in multiple tumor types [115]. However, recent evidence implicating DNA-PK
in pathways outside of NHEJ may help define novel strategies of therapeutic intervention, a
concept supported by the reality that all of the agents targeting DNA-PK currently in clinical
trial reflect the dynamic ability of DNA-PK to impinge on multiple pathways. CC-122 is a
DNA-PK inhibitor in phase I clinical trial (NCT01421524) for solid tumors, Non-Hodgkin’s
lymphoma, and multiple myeloma. CC-122 is described as a pleiotropic pathway modifier,
echoing the ability of DNA-PK to modulate numerous pathways outside of double strand
break repair. The two additional DNA-PK targeting molecules currently in clinical trial
target both DNA-PK and the PI3K/Akt/mTOR signaling pathway. CC-115 is a dual inhibitor
of DNA-PK and mTOR, and is currently in phase I trial (NCT01353625) for advanced solid
tumors and hematologic malignancies while ZSTK474 is a PI3K inhibitor that also inhibits
DNA-PK currently in phase I trials (NCT01280487 and NCT01682473) for advanced solid
malignancies. As the only DNA-PK-targeting compounds currently in clinical trial impinge
on pathways outside of DNA-PK-mediated damage repair, it will be important to consider
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novel DNA-PK regulated pathways when designing therapeutic strategies. For example, as a
positive feedback circuit involving AR and DNA-PK drives PCa progression and survival,
next generation means of targeting AR activity in combination with a DNA-PK inhibitor
may represent a novel node of therapeutic intervention in advanced PCa. Though directly
targeting cancer tissue is always important to consider with double strand break-inducing
agents to avoid reduction of the therapeutic ratio, such combination strategies could afford
new opportunities for precision therapies since DNA-PK seems to impact multiple tumor
types.
FUTURE DIRECTIONS
Findings discussed herein illustrate that DNA-PK has dual functions in both DNA repair and
gene regulation that promote tumor cell survival and progression, both in the presence and
absence of genomic damage. These discoveries shed light on the potential mechanisms
underlying DNA-PK-associated tumor phenotypes and poor outcomes associated with high
DNA-PK expression. Key questions remain which will facilitate further understanding of
DNA-PK-mediated tumor progression, and illuminate the overall consequence of targeting
this kinase in human malignancy. First, precisely how is DNA-PKcs activated, and is the
mechanism of activation altered in the context of cancer? While autophosphorylation of
multiple sites denotes activation, the factors and events preceding the phosphorylation event
are incompletely defined. Recent findings suggest that factors other than the Ku70/Ku80
heterodimer and DNA ends may assist in activation, and the factors influencing DNA-PKcs
activation may be context dependent. Discovery and understanding of how and when
different factors impact DNA-PKcs activation will provide insight into how DNA-PKcs
impacts disease progression and identify new therapeutic targets. Second, what dictates the
specificity of DNA-PKcs-mediated transcriptional regulation in cancer cells? DNA-PKcs
has been defined as a transcriptional modulator in multiple contexts, but the global impact of
DNA-PKcs on transcription has yet to be considered. Discovery of gene expression
networks impacted by DNA-PKcs and understanding of specific cofactors involved will
identify how DNA-PKcs damage-independent activation drives tumor survival. While recent
studies have contributed some understanding to this issue, global discernment of the
transcriptional function of DNA-PKcs in addition to the damage response function will
provide disease-specific insight into progression. Third, which functions of DNA-PKcs
should be considered when designing therapeutic strategies? Though the roles of DNA-
PKcs in damage repair and genomic stability are currently integrated into therapeutic tactics,
the transcriptional roles of DNA-PKcs have not been well considered when designing
preclinical studies and clinical trials. Further, while the DNA-PK inhibitors entering clinical
trial for cancer are known to inhibit the kinase activity of the protein, little is known
regarding kinase-independent functions of DNA-PKcs that may impact therapeutic efficacy
in targeting malignancy. Finally, does the function of DNA-PKcs change during cancer
progression? One hallmark in progression of cancer (and other diseases) is alteration of
signaling and regulatory pathways. While DNA-PKcs is generally considered a tumor
suppressor under normal growth conditions, it acts more as a tumor promoter in cancerous
cells, aiding in resistance to genotoxic therapeutics. Further, the effects of DNA-PKcs
mutations recently identified in numerous cancer types should be determined in the contexts
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of transcriptional regulation and cancer progression. It will be critical to ascertain if
modulators and/or substrates of DNA-PKcs change as cancers progress and mutate,
particularly when designing therapeutic strategies aimed at specific stages of disease.
The continual discovery of novel means of regulation and roles of DNA-PK suggests that
despite recent advances, thorough understanding of the cellular responsibilities of DNA-PK
has yet to be realized. Additional studies regarding context dependent mechanisms of
activation, global impact on transcription, kinase-independent functions, and alteration of
function and regulation during cancer development and progression are needed to further
characterize the function of DNA-PK, as each new advance may define a novel therapeutic
strategy in any number of cancer types. While DNA-PK is certainly a critical component of
the cellular response to DNA damage, it is clear that DNA-PK exerts pleiotropic cellular
roles that yield major impact on human malignancies.
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STATEMENT OF SIGNIFICANCE
While classically considered a component of damage response, recent findings illuminate
damage-independent functions of DNA-PK that impact multiple tumor-associated
pathways and provide rationale for development of novel therapeutic strategies.
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Figure 1.
(A) DNA-PKcs is composed of multiple functional domains and (B) influences DNA double
strand break repair through both the non-homologous end joining and homologous
recombination pathways.
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Figure 2.
DNA-PKcs is activated through multiple mechanisms.
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Figure 3.
DNAP-Kcs modulates tumor-associated cellular pathways
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Figure 4.
DNA-PKcs regulates transcription through interaction with multiple factors in a variety of
contexts.
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